Trials / Recruiting
RecruitingNCT07046923
A Study of LY4175408 in Participants With Advanced Cancer
A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4175408, an Antibody Drug Conjugate Targeting Protein Tyrosine Kinase 7-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 240 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. Participation could last up to 4 years.
Conditions
- Carcinoma, Non-Small-Cell Lung
- Small Cell Lung Carcinoma
- Endometrial Neoplasms
- Neoplasm Metastasis
- Triple Negative Breast Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY4175408 | IV infusion |
Timeline
- Start date
- 2025-07-28
- Primary completion
- 2030-07-01
- Completion
- 2030-07-01
- First posted
- 2025-07-02
- Last updated
- 2026-04-17
Locations
25 sites across 6 countries: United States, China, France, Japan, South Korea, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07046923. Inclusion in this directory is not an endorsement.